Mutations in the PIK3CA gene are present in about 4% to 36% of cancers such as breast, ovarian, endometrial and colorectal cancer, among others.

Bright Biologics LLC reported the discovery and preclinical evaluation of BB-203, an anti-PD-L1/anti-VEGF bispecific antibody (Ab) being developed for the treatment of cancer.

Urocortin-2 (UCN2) is a selective corticotropin-releasing factor CRF2 receptor (CRFR2) agonist, which has been previously shown to reduce fat mass while promoting muscle hypertrophy. Hanmi Pharmaceutical Co. Ltd. presented the discovery and preclinical characterization of a novel CRFR2-selective UCN2 analogue, HM-17321, being developed for the treatment of obesity.

Enanta Pharmaceuticals Inc. has released preclinical pharmacokinetics (PK) data for EDP-514, a potent and selective class II core assembly modulator in phase I development for the oral treatment of hepatitis B.

Researchers from Ohio State University hypothesized that 12,13-diHOME may act by inhibiting the proarrhythmic molecule Ca2+/calmodulin-dependent kinase II (CaMKII).

The efficacy and capabilities of CVI Pharmaceuticals Inc.'s CVI-2742, a THR-β agonist, were tested in nonhuman primates.

As a consequence of chronic liver disease progression, severe cirrhosis, decompensation and fibrosis culminates in end-stage liver disease (ESLD). There are no treatment options approved for ESLD, but, among others, regenerative therapies with autologous, nonengineered, pro-regenerative macrophages have shown good tolerability and improved transplant-free survival in the clinical setting.